Announcements Trials

Browse Landscape

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ovarian Neoplasms × saracatinib × Clear all

Phase

Phase 2/3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Neoplasms 2 Breast Neoplasms 2 Tongue Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma, Endometrial Stromal 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1 Rectal Neoplasms 1 Pleural Effusion, Malignant 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Melanoma 1 Liposarcoma 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Fibrosarcoma 1 Esophageal Neoplasms 1 Dermatofibrosarcoma 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms, Male 1 Bone Neoplasms 1 Bone Diseases 1

Interventions

Paclitaxel 135 Carboplatin 130 Bevacizumab 86 Gemcitabine 45 pembrolizumab 37 olaparib 34 liposomal doxorubicin 30 Cisplatin 30 Docetaxel 29 Cyclophosphamide 29 Topotecan 28 niraparib 27 Taxes 21 Etoposide 18 Doxorubicin 17 Filgrastim 16 Immunoglobulin G 15 Disulfides 15 apatinib 12 Letrozole 12 Albumin-Bound Paclitaxel 12 Drug Therapy 11 fluzoparib 10 fludarabine 10 Specimen Handling 10 Magnetic Resonance Spectroscopy 10 Biopsy 10 durvalumab 9 Nivolumab 9 pazopanib 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00610714 2012-12-18

OVERT-1

AstraZeneca

Phase 2 Completed

211 enrolled 12 charts

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡